Medtronic (NYSE:MDT) announced growth in three out of four segments for the third quarter, with diabetes the only one to slide year-over-year. The Fridley, Minnesota-based medtech giant saw third-quarter revenue growth in its cardiovascular segment (3.4%), medical-surgical segment (1.2%) and neuroscience segment (0.8). However, the company’s diabetes business dipped 7.3% year-over-year in sales. In December 2021, […]
MassDevice Earnings Roundup
Dexcom misses on EPS in Q4
Dexcom (NSDQ:DXCM) shares are down slightly, a day after fourth-quarter results that were mixed compared to the consensus forecast. The San Diego-based continuous glucose monitoring technology developer yesterday evening posted losses of $19.4 million, or 20¢ per share, on sales of $698.2 million for the three months ended Dec. 31, 2021, for a bottom-line slide […]
Teva rises on mixed-bag Q4, sets 2022 guidance
Teva Pharmaceuticals (NYSE:TEVA) shares ticked up this morning on fourth-quarter results that topped the consensus EPS forecast. The Tel Aviv, Israel–based company posted losses of $159 million, or 14¢ per share, on sales of $4.1 billion for the three months ended Dec. 31, 2021, for a bottom-line slide into the red on a sales decline […]
Senseonics posts Q3 earnings beat, hopes for new FDA approval soon
Senseonics (NYSE:SENS) shares ticked up slightly on third-quarter results that beat the consensus earnings forecast. The Germantown, Maryland-based company posted profits of $42.9 million, or 8¢ per share, on sales of $3.5 million for the three months ended Sept. 30, 2021, for a massive bottom-line swing out of the red on sales growth of nearly […]
Stevanato Group beats The Street in Q3, raises guidance
Stevanato Group (NYSE:STVN) shares hit a snag today despite third-quarter results that beat the consensus forecast. The Piombino Dese, Italy-based drug delivery technology developer posted profits of $21.6 million, or 8¢ per share, on sales of $248.6 million for the three months ended Sept. 30, 2021, for a 12.5% bottom-line gain on sales growth of […]
Insulet posts Q3 sales beat, remains on track for Omnipod 5 clearance
Insulet (NSDQ:PODD) shares ticked up today on third-quarter results that were mixed compared to the consensus forecast. The Acton, Massachusetts-based tubeless insulin pump technology developer posted profits of $12.6 million, or 18¢ per share, on sales of $275.6 million for the three months ended Sept. 30, 2021, for an 8.6% bottom-line gain on sales growth […]
BD ticks up on Street-beating Q4, sets 2022 guidance range
BD (NYSE:BDX) shares rose today on fourth-quarter results that came in ahead of the consensus forecast. The Franklin Lakes, New Jersey-based medtech posted profits of $242 million, or 84¢ per share, on sales of $5.1 billion for the three months ended Sept. 30, 2021, more than doubling its bottom line on sales growth of 7.3%. Get […]
Tandem nosedives after hours despite strong Q3, raised guidance
Tandem Diabetes Care (NSDQ:TNDM) shares took a massive hit after hours today on third-quarter results that beat the consensus forecast. TNDM shares were down 12.3% at $124.01 per share after the markets closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 0.1%. The […]
Catalent beats The Street in Q1, raises revenue guidance
Catalent (NYSE:CTLT) shares dipped today despite first-quarter financial results that beat the consensus forecast. The Somerset, New Jersey-based company posted profits of $93 million, or 49¢ per share, on sales of $1.025 billion for the three months ended Sept. 30, 2021, for a 13.4% bottom-line gain on sales growth of 21.2%. Get the full story at […]
Dexcom raises guidance ahead of G7 launch, FDA submission imminent
Dexcom (NYSE:DXCM) shares are up more than 9% today — a day after the company announced it will soon formally seek FDA clearance for its next-gen G7 system. The San Diego-based diabetes management technology developer yesterday evening posted profits of $70.9 million, or 71¢ per share, on sales of $650.2 million for the three months […]